Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711464 · ClinicalTrials.gov registry record · Phase 4
Modafinil Effects on Cognition in Schizophrenia Patients
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT00711464 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 29 participants.
The verdict
NCT00711464, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language. These problems may explain why patients with schizophrenia think and act in unusual ways, and often have problems managing aspects of their lives that healthy adults take for granted. Unfortunately, the biochemical aspects of these dysfunctions are presently unknown, and it is not clear whether current psychiatric medications can improve these functions. A recent FDA-approved medication that may improve this function is modafinil. Studies in animals and healthy adults show that this medication can improve many of these cognitive functions. We plan to study the effects of modafinil on these cognitive processes, by giving various doses of this medication to patients before they perform tasks of these cognitive processes. We predict that when patients receive modafinil, they will perform better on a cognitive test, and that these benefits will depend on the dose given.
Interventions
- DRUG modafinil (M1, M2, M4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711464
The ClinicalTrials.gov registry entry for NCT00711464 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which modafinil (M1, M2, M4) is the first listed.
NCT00711464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00711464 about?
NCT00711464 is a clinical study titled "Modafinil Effects on Cognition in Schizophrenia Patients". Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language. These problems may explain why patients with schizophrenia think and act in unusual ways, and often have problems manag...
What is the current status of trial NCT00711464?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2008-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00711464?
The interventions under investigation include: modafinil (M1, M2, M4) (DRUG).
Who is sponsoring clinical trial NCT00711464?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.